RayzeBio Inc

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rayzebio, Inc. provides radiopharmaceutical medicines for cancer. It develops a pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225. The company was founded by Deborah Charych, Aaron Kantoff and Aron Royston in January 2020 and is headquartered in San Diego, CA.

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Tim Van Hauwermeiren to its board of directors. As co-founder and CEO of argenx, Tim has built a reputation for his strong execution and innovation, leading argenx from early-stage development into a global immunology company.

RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, representing a 110% upside. The company's radiopharmaceutical technology could revolutionize the cancer treatment landscape. RYZ801 has shown promise in GPC3 expressing hepatocellular cancers.

RayzeBio: Initiating Coverage With Buy Rating And A Price Target Of $43

RayzeBio's stock has fallen near its original IPO price, presenting an attractive buying opportunity. RYZB's lead drug in Phase-3 clinical testing has best-in-class potential for the treatment of solid tumors. The valuation is reasonable based on the peak sales projections of their clinical stage drugs.

RayzeBio: Raising The Bar In Solid Tumor Radiotherapy

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters' option to purchase up to 2,591,640 additional shares from RayzeBio, at a price to the public of $18.00 per share. RayzeBio sold 18,706.

RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

ARM Holdings PLC

Birkenstock Holding Plc

Instacart (Maplebear Inc.)

The initial public offering (IPO) market is on track to continue accelerating in the last few months of 2023 and into the new year following a series of impressive debuts after a lull in high-profile listings. This week, ARM Holdings and RayzeBio both made a splash with their respective listings.

IPO market recovering with strong ARM and RayzeBio debuts; Instacart, Birkenstock and more to come

Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% above the initial public offering price. The company had raised $311 million as it sold 17.3 million shares in the IPO, up from an expected 14.4 million shares, with the IPO pricing at $18 a share, at the top of the expected range.

RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion

RayzeBio Inc shares are expected to begin trading on the Nasdaq after Friday's open as the radiopharmaceutical company's upsized initial public offering (IPO) priced at the top end of the expected range.  The company announced that it has offered 17.28 million shares in the IPO, up from previous expectations of 14.4 million shares, priced at $18 per share to raise $311.0 million.

RayzeBio to go public at $1B market valuation

RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offering priced at the top end of the expected range. The company said it offered 17.28 million shares in the IPO, up from previous expectations of 14.4 million shares, to raise $311.0 million.

RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the pricing of its upsized $311 million initial public offering of 17,277,600 shares of common stock at a price to the public of $18.00 per share. RayzeBio is offering 16,114,600 shares of common stock and the selling stockholder named in the prospectus is offering 1,163,000 shares of common stock. RayzeBio wil.

RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering

RayzeBio has filed for a $245 million IPO to develop radiopharmaceutical treatments for cancer. The company's lead candidate, RYZ101, is entering Phase 3 trials for the treatment of gastroenteropancreatic neuroendocrine tumors. The global market for solid tumor cancer treatments is projected to reach $532 billion by 2032, driving the growth of companies in this sector.

IPO Update: RayzeBio Readies $245 Million IPO

RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Phase 3 trial looks to raise up to about $238.2 million. A total of 14.4 million shares will be offered in the IPO, with the company offering 13.2 million shares and a selling shareholder offering 1.2 million shares.

RayzeBio sets IPO terms, to be valued at up to $1 billion

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of directors. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry as a board member and executive, serving in various commercial and portfolio management roles at Genentech, Inc., Roche Holding AG and Schering-Plough Corporation. “I am very excited about the impact RayzeBio ca.

RayzeBio Appoints Christy Oliger to its Board of Directors

RayzeBio, Inc. has filed for a $100 million IPO to fund the development of its radiopharmaceutical treatments for cancer. The company's lead candidate program, RYZ101, is enrolling patients for a Phase 3 trial for the treatment of gastroenteropancreatic neuroendocrine tumors. RayzeBio has extensive resources and strong backing from life science investors to support its development programs.

Late Stage Biopharma RayzeBio Files For U.S. IPO

News for RayzeBio Inc Stock (RYZB)